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INTRODUCTION
Tuberous sclerosis complex (TSC) is a genetic disorder known to have a multi-system,
neurocutaneous clinical presentation with an estimated incidence of 1 per 6,000 to 10,000 live
births (1). The characteristic findings of TSC are skin lesions, seizures, hamartomas in the
brain, kidneys, and heart in addition to a spectrum of neuropsychiatric conditions. The clinical
manifestations of TSC show inter- and intra-familial variable expressivity and have the
potential to fluctuate in severity over an affected individual’s lifetime (2, 3). The
pathophysiology of TSC arises from a heterozygous pathogenic variant in the tumor
suppressor genes TSC1 and TSC2 that encode the instructions for the proteins hamartin and
tuberin, respectively (4, 5). Consequently, the amount of functional protein is reduced, but the
other copy provides enough products to effectively regulate cell growth. A second somatic
pathogenic variant in TSC1 or TSC2 can lead to insufficient production of hamartin or tuberin
and causes uncontrolled cell growth and division, resulting in hamartomas across multiple
organ systems (6, 7). The pathohysiology of other clinical features associated with TSC is less
well-understood.
At the 2012 International TSC Consensus Conference, the Neuropsychiatry Panel
expressed concern regarding the 70% treatment gap and lack of uniformity in terminology
regarding the non-physical manifestations associated with TSC (8). The term “treatment gap”
refers to the difference between the portion of the population in need of services compared to
the portion of the population actually receiving appropriate services (9). The members of the
2012 International TSC Consensus Conference showed support for the previously coined term,
TAND, or TSC-Associated Neuropsychiatric Disorders, in order to collectively represent the
various domains of neuropsychiatric manifestations within the continuum of TSC symptoms
(8, 10). In order to address the treatment gap, the TAND checklist was developed and later
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validated to serve as a screening tool for clinicians. The TAND checklist serves as a
streamlined method to identify the concern for neuropsychiatric manifestations with the
ultimate goal of prompt and precise diagnosis as well as effective management of symptoms
(11, 12). Along with the development of the TAND checklist, the recommendation was made
for all individuals with TSC to undergo annual neuropsychiatric screening (12). It has been
previously determined that 90% of children and adults with TSC will experience symptoms
associated with TAND at some point during their lifetime, but fewer than 20% them will ever
receive an appropriate TAND assessment and/or treatment (12). The 70% treatment gap for
neuropsychiatric conditions in the TSC community is similarly observed in global studies
regarding utilization of mental health care treatment (13, 14). Poor physical health in addition
to poor mental health can contribute to a lower quality of life. It is therefore important to
address the TAND treatment gap in the TSC community and provide opportunities to improve
quality of life through the utilization of mental health services.
Even though treatment for mental health conditions has been documented as effective,
there remain significant attitudinal and structural barriers that individuals struggle to overcome
to reach proper mental health care services (15, 16). Structural barriers, such as treatment
availability, geographical access, and financial capability, continue to be important hurdles to
obtaining mental health treatment. Attitudinal barriers, such as the negative connotation and
stigma associated with undergoing mental health treatment, are more frequently reported in
comparison to structural barriers as the cause behind lack of initiating as well as continuing
treatment (17, 18). Unfortunately, the consequences of stigma lead to symptom denial and
delay in treatment. Through education of the general public as well as healthcare providers, a
reduction in negative beliefs and stigma of mental illnesses can contribute to elimination of
barriers toward mental health treatment. The purpose of our study is to provide clinicians and
2

members of the TSC community with a more intimate, first-hand look into the impact of
neuropsychiatric manifestations of TSC. Through a multi-faceted survey, our study evaluated
perception of disease severity, presence of anxiety and depression, as well as the barriers and
utilization of mental health services among adults with a diagnosis of TSC.
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MATERIAL AND METHODS
Our study used a cross-sectional, web-based approach to survey adults with TSC. The
electronic survey was designed using the Qualtrics online software (Qualtrics, Provo, UT). The
survey components and recruitment strategy were developed by the authors and approved by
the University of Texas Health Science Center at Houston Institutional Review Board (HSCMS-17-0599). Data collection was performed from November 2017 through February 2018.
Each participant provided consent electronically before completing the 30-minute survey. All
survey responses were anonymous. To compensate for their time, participants who completed
the survey were given the opportunity to provide a valid mailing address to receive a $5.00 gift
card. The survey responses were kept separately from the mailing addresses.
Study sample
Participants were recruited via email through the Tuberous Sclerosis (TS) Alliance.
The TS Alliance Adult Regional Coordinators sent the survey to their constituents a minimum
of three times over the previously mentioned time frame. Additionally, the researchers
approached eligible participants in the TSC clinic at University of Texas Health Science
Center at Houston. If they agreed to participate, then they were given an iPad to use in clinic to
complete the survey. The eligibility criteria for both electronic and clinical participants
included having a diagnosis of TSC, being 18 years or older, as well as having the ability to
independently complete a 30-minute electronic survey. Eligible participants were first directed
to the consent page. Once electronic consent was obtained, participants proceeded with the
survey.
Survey components
The structure of the survey included questions to determine the participant’s clinical
care setting, evaluate their perception of disease severity, measure levels of depression and
4

anxiety, as well as their use and perspectives on mental health care services. Demographic
information including age, sex, ethnicity, years since TSC diagnosis, occupation, income, and
type of insurance was collected for all participants. The survey design set out to assess the
influence of a person’s perception of disease severity on mental health and utilization of
mental health care services.
The standardized and validated measures used in the survey included the Brief-Illness
Perceptions Questionnaire (Brief-IPQ), Beck Anxiety Inventory (BAI), and Beck Depression
Inventory-II (BDI-II). The Brief- IPQ was designed to provide a quick assessment of illness
perceptions through single item questions on a scale from 0 to 10 to assess the severity of eight
different dimension (19). The dimensions included “perceived consequences of their illness,
timeline, perceived personal control, treatment control, identity, concern about the illness,
coherence of illness, and emotional representation” (19). Permission to use the Brief-IPQ was
obtained from the original authors. The BAI is the most widely used diagnostic instrument to
discriminate between anxious and non-anxious groups (20, 21). The tool consists of 21-self
reported items that assess for common symptoms of anxiety that have occurred during the past
week including “numbness, feeling hot, nervousness, unsteadiness, dizziness, heart racing, fear
of losing control, feeling scared, difficulty breathing, feeling faint, inability to relax and
discomfort in the abdomen.” Each item is answered on a Likert scale ranging from 0 to 3 and
the total score of all the items indicates whether the respondent has a low, moderate, or severe
level of anxiety (22). The Beck Depression Inventory-II, or BDI-II, is one of the more
extensively used self-reported measures for depression (23). It is comprised of 21-self reported
items with a Likert scale ranging from 0 to 3. The Beck Depression Inventory-II (BDI-II) is a
21-item, self-rated scale that evaluates key symptoms of depression having occurred during the
past two weeks including “sadness, pessimism, past failure, loss of pleasure, guilty feelings,
5

punishment feelings, self-dislike, self-criticalness, suicidal thoughts or wishes, crying,
agitation, loss of interest in activities, indecisiveness, worthlessness, loss of energy, change in
sleeping pattern, irritability, changes in appetite, difficulty in concentration, tiredness, and loss
of interest in sex” (23, 24). The total score indicates the presence as well as the severity of the
depression in the respondent. Permission to use and reproduce both the BAI and BDI-II was
obtained through Pearson Education.
Statistical analysis
All data was extracted from Qualtrics and analysis was performed using Stata (v. 14,
College Station, TX). Categorical variables were described using frequencies (with
percentages). Medians (with interquartile range, IQR) and means (with standard deviation, sd)
were used to describe continuous data that was not normally and normally distributed,
respectively. Categorical variables were compared across groups using contingency tests
(Fisher exact or Chi-square). Distributions of continuous variables were compared across
groups using a Mann-Whitney test (for comparisons between two groups) or a Kruskal-Wallis
test with post-hoc Dunn's test (for comparisons between more than two groups). To analyze
the impact of stigma and cost as a barrier to the utilization of mental health resources, values
were assigned to each response with 5 representing strongly agree and 1 representing strongly
disagree. Then, for each participant the response value for cost as a barrier was subtracted
from their response value for is stigma a barrier, which assigned respondents an overall
positive, negative, or zero response value. Spearman's correlation coefficients were utilized to
assess relationships between BDI-II, BAI and Brief-IPQ scores. Statistical significance was
assumed at a Type I error rate of 5%.

6

RESULTS
Demographics and Clinical Experience
The data collection process and demographic information of the 71 participants is
listed Table 1 and illustrated in Figure 1. The average age of the study participants was 43.7
years old (sd 13.2). The majority of respondents were Caucasian (88%, n = 62), female (73%,
n = 52), and received their initial clinical diagnosis of TSC over 10 years ago (86%, n = 61).
Of the 71 respondents, over a quarter (28%, n = 20) reported receiving a diagnosis of
intellectual disability. In regards to clinical experience, 39% (n = 28) reported receiving care in
a multidisciplinary setting, while 61% (n = 43) reported a non-multidisciplinary clinical care
setting. In our study, a multidisciplinary clinical care setting was defined as seeing multiple
doctors from different specialties in a single clinic visit. A non-multidisciplinary clinic was
defined as seeing a single specialty or multiple specialties in independent clinic visits. Out of
the 43 individuals who reported receiving care in a non-multidisciplinary clinical setting, just
over a quarter (28%, n = 12) reported not having any medical provider for their TSC diagnosis.
From the 28 respondents who reported receiving care in a multidisciplinary clinic, the most
frequently seen specialties were neurology and nephrology at 35% and 28%, respectively. The
least commonly seen specialties in a multidisciplinary setting were psychiatry and
endocrinology at 2% each. The most frequently reported specialties seen in a nonmultidisciplinary setting (n = 31) were neurology and nephrology at 25% and 18%,
respectively. The least commonly seen specialty in a non-multidisciplinary clinic setting was
genetics at 2%. Respondents who reported receiving care in a multidisciplinary setting also
reported being seen by more physicians in the past year (median: 2; IQR: 1-3) compared to
respondents receiving care in a non-multidisciplinary clinic (median: 1; IQR: 0-3) (p=0.007).
Additionally, these same multidisciplinary clinic patients made significantly fewer clinic visits
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in the last year (median: 1; IQR: 0-2) compared to the non-multidisciplinary clinic patients
(median: 2; IQR: 1-4) (p=0.009).

Figure 1: Breakdown of Survey Responses
Total Number Surveys
Returned:
n = 80

Duplicated Surveys
Didn’t have TSC
Completed Demographic Information
Only:
n=9

Completed Demographics:
n = 71

Completed Clinical Experience:
n = 71
Completed Beck Anxiety Inventory:
n = 71
Completed Beck Depression InventoryII:
n = 69
Completed Brief-Illness Perception
Questionnaire:
n = 69
Completed Utilization of Mental Health
Services:
n = 69
Figure 1 shows the breakdown of responses by highlighting the number of surveys
returned, respondents who did not meet inclusion criteria, as well as the total sample
size for each of the six components of the survey.
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Table 1: Participant Demographics
Age
Percent (%)
Mean (SD)
43.7 (13.2)
18-24
10%
25-34
14%
35-44
32%
45-54
13%
55 +
31%
Years since TSC Diagnosis
1-10
14%
11-20
27%
>20
59%
Diagnosis of Intellectual Disability
Yes
28%
No
72%
Sex
Female
73%
Male
25%
Non-Binary
2%
Race
Asian
3%
African American
1%
Caucasian
88%
Native American
1%
Pacific Islander
1%
Other
6%
Annual Household Income
< $24,999
27%
$25,000 - $49,999
18%
$50,000 - $74,999
16%
$75,000 - $99,999
3%
> $100,000
18%
Prefer to not respond
18%
Country of Residence
United States
98%
Canada
1%
Other
1%
Education Level
High School/GED Less
22%
Trade School
6%
Some College
23%
Bachelor’s Degree
32%
Graduate Degree
17%
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BAI Results
The overall median score for BAI was 8 (IQR 3-14) with no statistical significant
differences between the median score between men and women (Table 2). Comparisons of the
BAI scores for the individual BAI items and compared across stratifications by intellectual
disability, education, and TSC disease severity. The p-values were controlled for Type I errors
and are presented in Table 3A. Nearly all of the BAI items, excluding unsteadiness, hands
trembling, feelings of choking, and face flushed, showed a statistically significant relationship
demonstrating more severe symptoms of anxiety in individuals who self-reported higher levels
of TSC disease severity. Similarly, the majority of BAI components, with the exception of
feeling hot, feelings of choking, hands trembling, face flushed, and sweating (not due to heat),
showed a statistically significant trend in which individuals with intellectual disabilities who
have TSC indicated more severe anxiety related symptoms. Additionally, respondents with
some level of higher education indicated a statistically significant increase in severity of
anxiety related symptoms including feelings of choking, terrified, fear of losing control,
feeling faint, wobbliness, feeling dizzy or lightheaded, and difficulty breathing. There was no
significant correlation between intellectual disability and education level.
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Table 2: BAI, BDI-II, and Brief-IPQ Scores
Median (25th-75th)
BAI

8 (3 – 14)
Women

7 (3 – 11)

Men

10.5 (4 – 17)

BDI-II

8 (2 – 20.5)
Women

7 (2 – 16)*

Men

22 (6 – 26)*

Brief-IPQ

45.5 (35.5 – 53.5)

Women

45 (35 – 54)

Men

47 (40 – 53)

Table 3A: BAI Item Analysis
Numbness or tingling
Feeling Hot
Wobbliness in legs
Unable to relax
Fear of the worst happening
Dizzy or lightheaded
Heart Pounding or racing
Unsteady
Terrified
Nervous
Feelings of choking
Hands trembling
Shaky
Fear of losing control
Difficulty breathing
Fear of dying
Scared
Indigestion/discomfort in abdomen
Faint
Face flushed
Sweating (not due to heat)

Intellectual
Disability
0.001
0.302
0.001
0.021
0.002
0.001
0.022
0.000
0.004
0.001
0.228
0.260
0.000
0.001
0.007
0.001
0.003
0.025
0.000
0.074
0.274
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Education
Level
0.552
0.496
0.036
0.192
0.187
0.049
0.120
0.099
0.009
0.169
0.088
0.323
0.687
0.013
0.036
0.301
0.062
0.127
0.036
0.190
0.193

Disease
Severity
0.017
0.015
0.005
0.016
0.005
0.013
0.237
0.002
0.002
0.000
0.140
0.506
0.002
0.003
0.000
0.001
0.000
0.003
0.000
0.213
0.007

BDI-II and Brief-IPQ Results
The overall median score for BDI-II was 8 (IQR 2-20.5; Table 2). The difference
between the median BDI-II score for men and women was statistically significant with men
scoring higher than the females (p = 0.023; Table 2). Comparisons of the BDI-II scores for the
individual BDI-II items were compared across stratifications by intellectual disability,
education, and TSC disease severity. The p-values were controlled for Type I errors and
presented in Table 3B. Slightly fewer than half of the BDI-II items (9 out of 21), including
sadness, pessimism, suicidal thoughts or wishes, indecisiveness, worthlessness, change in
appetite, difficulty concentrating, and loss of interest in sex, showed a statistically significant
relationship demonstrating more severe symptoms in individuals who self-reported higher
levels of TSC disease severity. Individuals with a diagnosis of intellectual disability
demonstrated a statistically significant increase in severity of depression symptoms, including
the BDI-II items of sadness, pessimism, indecisiveness, loss of energy, change in appetite,
difficulty concentrating, and tiredness. Similarly, respondents with some level of higher
education illustrated a statistically significant increase in the BDI-II items of self-dislike and
worthlessness. There was no significant correlation between intellectual disability and
education level. The overall median for the Brief-IPQ was 45.5 (IQR 35.5 - 53.5) with no
statistically significant differences between men and women (Table 2).
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Table 3B: BDI-II Item Analysis
Sadness
Pessimism
Past Failure
Loss of Pleasure
Guilty Feelings
Punishment
Self-Dislike
Self-Criticalness
Suicidal Thoughts or Wishes
Crying
Agitation
Lost of Interest
Indecisiveness
Worthlessness
Loss of Energy
Change in Sleeping Pattern
Irritability
Change in Appetite
Difficulty in Concentrating
Tiredness or Fatigue
Loss of Interest in Sex

Intellectual
Disability

Education
Level

Disease
Severity

0.001
0.043
0.361
0.178
0.086
0.986
0.148
0.332
0.313
0.551
0.112
0.659
0.004
0.127
0.038
0.085
0.187
0.014
0.033
0.002
0.110

0.269
0.342
0.131
0.134
0.824
0.190
0.026
0.103
0.424
0.409
0.129
0.387
0.533
0.047
0.164
0.436
0.189
0.495
0.408
0.471
0.769

0.002
0.004
0.295
0.284
0.128
0.493
0.465
0.405
0.005
0.135
0.032
0.147
0.001
0.021
0.064
0.211
0.056
0.003
0.008
0.073
0.015

Barriers and Utilization of Mental Health Services
Out of 69 respondents, 57% (n = 39) reported receiving mental health treatment at
some point over their lifetime. Of the group of individuals with a history of receiving mental
health treatment, approximately 31% (n = 12) of them had not seen a mental health specialist
in the past year. In contrast, 56% (n = 22) of respondents from the treatment group reported
seeing a mental health specialist on a regular basis. Of these respondents who were receiving
mental health services, the majority of respondents either “strongly agreed” or “agreed” that
mental health treatment was meeting their needs (65%, n = 25) as well as improving their
overall mental health (74%, n = 29). From the group of individuals who had never previously
received mental health treatment (n = 30), 23% of them felt they had symptoms that could be
addressed by a mental health specialist and 67% of them either “strongly agreed” or “agreed”
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that they would feel comfortable asking their primary provider about mental health services.
The treatment group and the non-treatment group’s responses to stigma and cost as being
barriers to accessing mental health resources are shown in Figure 2. In regards to barriers to
accessing mental health services, about half of the individuals from the mental health treatment
group (n = 39, 51%) felt that cost would prevent continued use of services while only a fifth
(n=33, 21%) of the individuals from that group felt that stigma would prevent continued use of
services. Of the group of individuals with no previous use of mental health services, 27% (n =
8) of individuals felt cost would prevent initiating mental health treatment while 20% (n = 6)
of individuals felt that stigma would prevent initiating mental health treatment. There was no
statistically significant relationship between stigma and socioeconomic status (SES) as well as
cost and SES as a function of income, occupation or education.
Figure 2: Cost versus Stigma as Barriers to Accessing Mental Health Services

Figure 2 illustrates that cost was overall a more significant barrier to accessing mental health
resources in comparison to stigma. Positive values were indicative of cost being a more
prominent barrier than stigma and negative values were indicative of stigma being a more
prominent barrier than cost. The value of zero represents that the respondent felt stigma and cost
were equal barriers.
14

DISCUSSION
The study described here set out to evaluate perception of disease severity within the
adult TSC population. Overall, men and women both indicated a perception of moderate
disease severity. The Brief-IPQ outcome supports the medical community’s understanding of
the clinical features of TSC. The implication of a moderate level of disease severity stems
from the spectrum of symptoms and life-long nature of the condition that contributes to
feelings of little personal control over the disease. The results of our study bring attention to
the individual’s daily experiences with their disease, regardless of the medical provider’s
perception of their patient’s disease severity. Medical providers, as well as members of the
TSC community, could benefit from studies that develop evidence-based care guidelines
regarding the psychosocial impact of TSC in an effort to tailor and improve overall clinical
care.
Our study results showed a moderate association between one’s perception of disease
severity and self-reported depression and anxiety. There was a strong correlation between BAI
and BDI-II scores. Even though these tools were designed with the intent of discriminant
validity, previous studies have also indicated moderate to strong correlations between the BAI
and BDI-II (21, 25). Suggested explanations for this phenomenon include that depression and
anxiety often co-occur or that depression and anxiety are simply different points on the same
spectrum (26, 27). The correlation seen in our study further supports their interrelated nature
given that the BAI and BDI-II tools were developed to be complementary to each other. The
overall BAI and BDI-II scores of our study population correspond and build upon previous
neuropsychiatric co-morbidity studies that indicate that the chronic illness populations have
increased incidences of anxiety and depression (28-33).
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The analysis of each validated measure indicated a significant difference in the median
BDI-II score between men and women. Our results do not align with the previously
established trend of women typically having higher BDI-II scores in comparison to men, as
well as the general consensus that women are twice as likely to experience depression (34, 35).
The increased incidence of depression within the TSC community compared to the general
population is well known, but there has not been any previous evidence of men with TSC more
frequently experiencing depression than women with TSC. It is possible that the men in our
study feel more disenfranchised by their diagnosis and severity of TSC in comparison to the
women leading to heightened levels of depression. The literature regarding depression in men
has been growing in recent years. Current theories thought to contribute to depression in men
include difficulty in fulfilling gender roles, biological factors, and/or coping styles (36).
Furthermore, it has been determined that men demonstrate a wider range of depressive
symptoms that stray from the traditionally known symptoms; therefore, typical methods used
to diagnose depression could lead to under-diagnosis (37). Given the moderate level of
depression among the men in our study, it would be beneficial to further delve into the
etiology and risk factors that contribute to depression in men with TSC as well as in men with
other chronic illnesses.
There was no significant difference between the median BAI scores for men and
women with both sexes falling in the minimal to mild range of anxiety. Despite the lack of
significance, the trend of women scoring on average four points higher on the scale (as
outlined in the BAI manual) was not observed in our study population (22). Comparisons of
BAI and BDI-II items across stratifications, including intellectual disability, educational level,
and self-reported perception of disease severity, shed light on specific dimensions that showed
significant associations in our study. Given the exploratory nature, our results on these
16

variables should primarily offer guidance and tailoring options during clinical interactions with
patients. Further analysis of these variables on a larger scale would be needed to elucidate a
more definitive relationship between individual dimensions from the BAI and BDI-II and
demographic information. Any studies that can provide the medical community insight about
the complex impact of psychiatric conditions in individuals with a chronic illnesses will
augment quality of care in the clinical setting.
There are several limitations to our study design and the results. The response rate and
sample size were low, making it difficult to generalize the conclusions from the study to the
entire TSC community. There is likely a selection bias given that our study sample was
derived from English-speaking individuals on the TS Alliance listserv with Internet access or
those who receive their medical care at the University of Texas Health Science Center at
Houston. Another selection bias is the inclusion criteria requiring that the individual with TSC
must independently complete the survey. The independence required to complete the survey
inherently discourages individuals that are cognitively impaired or have more severe
phenotypes from participating in our survey. Lastly, our survey was conducted through an
anonymous online survey; therefore, any clinical information gathered during data collection
was unable to be confirmed by the researchers. Future research regarding how to appropriately
address the neuropsychiatric phenotype in the clinical setting should be conducted in order to
effectively change clinical management for these patients. Research opportunities, such as
evaluating the efficiency and usefulness of an annual visit with a genetic counselor to discuss
the TAND, will provide the evidence needed to improve the clinical outcomes for patients
with TSC.
Our study results further supports the mental health treatment gap seen in previous
studies in the TSC community (12, 38). In a recent quality of life study, adults and children
17

with TSC were identified to have significantly reduced quality of life in comparison to the
general population (39). Regardless of clinical care setting, our data suggest that the majority
of participants visited at least one medical provider each year. It is imperative for all medical
disciplines to routinely inquire about physical health changes in addition to changes in the
patient’s mental health during each clinical evaluation through the use of the TAND checklist.
In 2004 and 2005, the World Health Organization (WHO) published reports expressing that
mental health is intricately linked to physical health and is integral to one’s overall well-being
(40, 41). Specifically, quality of life consists of one’s well-being and life-satisfaction as well
as the ability to sufficiently function within society (42). Therefore, in order to support
individuals with TSC in reaching and maintaining optimal quality of life, providers must
continually assess their mental health from childhood to adulthood. Through appropriate
referrals and utilization of mental health treatment, individuals can obtain services that can
lessen disease burden, and in turn, improve quality of life. The burden of mental health
illnesses was further supported by the 2010 Global Burden Disease Study that highlighted the
worldwide impact of mental and substance use disorders, as they account for 7.4% of
disability-adjusted life years (DALYs1) worldwide (43). Within mental and substance use
disorders, depressive disorders and anxiety disorders accounted for over half of DALYs
making them the most prominent mental health illnesses worldwide (44). Likewise, the most
commonly reported neuropsychiatric manifestations in the pediatric and adult TSC population
are cognitive concerns, depression, and anxiety (38). Our data support previous studies that
have found individuals who receive mental health treatment report feeling that it does
1

Disability-adjusted life years (DALYs) reflect the overall burden of disease, which corresponds to the number

of years lost to disability, illness, or premature death. The loss of the equivalent of one year of full health equates
one DALY (42).
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improves their overall mental health (15, 16, 45). Furthermore, our results indicate that the
majority of individuals with TSC would feel comfortable asking their primary provider about
mental health resources and services; therefore, TSC patients would welcome integrating
routine mental health evaluations in each clinical interaction.
Given the general complexity of accessing mental health services, our study set out to
identify potential barriers to access specifically in the TSC community. The stigma of mental
health illnesses and cost of services are commonly known as attitudinal and structural barriers
to accessing mental health treatment. Interestingly, our study results indicated that stigma was
not considered a significant barrier to initiating or continuing to access mental health
resources. Our results relate and build upon a recent study conducted by Whitley et al, 2014.
The results of their study identified that individuals with mental health illnesses frequently
employ behavioral and psychological strategies to prevent or reduce problems associated with
stigma (46). Moreover, the view of mental health illnesses has evolved to be analogous with
physical illness (46). If society’s view of mental health continues to shift in a more accepting
and supportive direction, then stigma will diminish further and will progressively become less
of a barrier to mental health services (47). In regards to cost, the results of our study align with
the notion that cost is a persistent and increasing barrier among these individuals. With
increasing use of mental health services in conjunction with limited solutions to the issue of
cost or insurance coverage, individuals will continue to face barriers during utilization of these
resources (48-50).
In conclusion, disease severity had a moderate and low-moderate association with
anxiety and depression, respectively. Regardless of past utilization, respondents had a positive
outlook towards the use of mental health services with the major barrier being cost. All
healthcare providers seeing patients with TSC should use the readily available TAND
19

checklist. Specifically, the evaluation for neurobehavioral changes falls within the clinical
genetic counselor’s scope of practice. For the benefit of the TSC community, a genetic
counselor could undertake the responsibility of consistently assessing patients with TSC for
changes or new developments within the spectrum of TAND and subsequently refer any
patients in need of mental health services.
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